BR112012026644A2 - compostos antivirais - Google Patents

compostos antivirais

Info

Publication number
BR112012026644A2
BR112012026644A2 BR112012026644A BR112012026644A BR112012026644A2 BR 112012026644 A2 BR112012026644 A2 BR 112012026644A2 BR 112012026644 A BR112012026644 A BR 112012026644A BR 112012026644 A BR112012026644 A BR 112012026644A BR 112012026644 A2 BR112012026644 A2 BR 112012026644A2
Authority
BR
Brazil
Prior art keywords
compounds
antiviral compounds
rig
viral infection
reaction series
Prior art date
Application number
BR112012026644A
Other languages
English (en)
Inventor
Bedard Kristin
P Ladonato Shawn
Original Assignee
Kineta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta Inc filed Critical Kineta Inc
Publication of BR112012026644A2 publication Critical patent/BR112012026644A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32211—Cardiovirus, e.g. encephalomyocarditis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

compostos antivirais. descritos aqui são compostos e composições relacionadas para o tratamento de infecção viral, incluindo infecção de rna vira, e os compostos podem modular a série de reação rig-i em células de vertebrados, incluindo os compostos que podem ativar a série de reação rig-i.
BR112012026644A 2010-04-23 2011-04-20 compostos antivirais BR112012026644A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32757910P 2010-04-23 2010-04-23
PCT/US2011/033336 WO2011133728A2 (en) 2010-04-23 2011-04-20 Anti-viral compounds

Publications (1)

Publication Number Publication Date
BR112012026644A2 true BR112012026644A2 (pt) 2017-12-19

Family

ID=44815983

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012026644A BR112012026644A2 (pt) 2010-04-23 2011-04-20 compostos antivirais

Country Status (12)

Country Link
US (1) US9408826B2 (pt)
EP (1) EP2560652A4 (pt)
JP (1) JP2013527159A (pt)
KR (1) KR20130055612A (pt)
CN (1) CN102946881A (pt)
AU (1) AU2011242689B2 (pt)
BR (1) BR112012026644A2 (pt)
CA (1) CA2798209A1 (pt)
IL (1) IL222633A0 (pt)
MX (1) MX2012012354A (pt)
TW (1) TW201139419A (pt)
WO (1) WO2011133728A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133728A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
EP2918273B1 (en) 2011-02-25 2016-12-21 Kineta, Inc. Methods and cells for identifying rig-i pathway regulators
WO2013049352A2 (en) * 2011-09-30 2013-04-04 Kineta, Inc. Anti-viral compounds
US9073946B2 (en) * 2013-01-15 2015-07-07 Kineta, Inc. Anti-viral compounds
WO2014142645A1 (en) * 2013-03-15 2014-09-18 University Of Malaya Antiviral activity of quercetin against japanese encephalitis virus
MY188046A (en) * 2013-03-15 2021-11-12 Univ Malaya Antiviral activity of baicalein against japanese encephalitis virus
CA2915874A1 (en) * 2013-07-16 2015-01-22 Kineta, Inc. Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
CN104628717B (zh) * 2015-03-16 2017-02-15 湖南大学 3‑[5‑(1，2，4‑***‑1‑基)噻唑‑2‑基]苯并噁嗪及其应用
CN104829607B (zh) * 2015-05-11 2017-04-12 邵阳学院 N‑噻唑苯并噁嗪酮衍生物作为神经氨酸酶抑制剂的应用
US10376504B2 (en) 2015-07-29 2019-08-13 Merck, Sharp & Dohme Corp. Substituted quinolinones as PDE9 inhibitors
US10370336B2 (en) 2015-07-29 2019-08-06 Merck Sharp & Dohme Corp. Phenyl-cyanoquinolinone PDE9 inhibitors
WO2017019726A1 (en) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Oxy-cyanoquinolinone pde9 inhibitors
JP2018052878A (ja) 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2021026672A1 (en) 2019-08-09 2021-02-18 Novartis Ag Heterocyclic wdr5 inhibitors as anti-cancer compounds
KR20220064369A (ko) 2019-08-14 2022-05-18 인사이트 코포레이션 Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물
BR112022006977A2 (pt) 2019-10-11 2022-09-20 Incyte Corp Aminas bicíclicas como inibidores de cdk2
US11975106B2 (en) * 2020-03-26 2024-05-07 Provectus Pharmatech, Inc. Uses of halogenated xanthenes in oncology and virology
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0267218A (ja) * 1988-08-31 1990-03-07 Nagakura Seiyaku Kk ウイルス・ゲノム不活化剤
AU3456499A (en) * 1998-03-30 1999-10-18 University Of Mississippi, The Isoflavones for treating giardiasis and malaria
GB9920912D0 (en) * 1999-09-03 1999-11-10 Indena Spa Novel derivatives of flavones,xanthones and coumarins
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US7902253B2 (en) 2003-05-15 2011-03-08 Chengdu Dikang Pharmaceutical Institute Isoflavone derivatives of tectorigenin, the preparation thereof and the antiviral medicine containing the same as an effective constituent
WO2005103039A1 (en) 2004-04-15 2005-11-03 Neurocrine Biosciences, Inc. 2- (3-aminopyrrolidin-1-yl) pyridines as melanin-concentrating hormone receptor an tagonists
GB0412768D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
WO2006002422A2 (en) * 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
WO2006034219A2 (en) * 2004-09-17 2006-03-30 The General Hospital Corporation Inactivation of microorganisms with multidrug resistance inhibitors and phenothiaziniums
AU2007294752A1 (en) * 2006-09-14 2008-03-20 Synta Pharmaceuticals Corp. Compounds for the treatment of angiogenesis
CA2667972A1 (en) 2006-10-30 2008-05-08 Michael Tovey Gene reporter assay, kit and cells with improved sensitivity and/or specificity for determining the level of an extracellular signal
WO2008080091A2 (en) 2006-12-21 2008-07-03 Vical Incorporated Activation of rig-i pathway
WO2008134372A2 (en) 2007-04-26 2008-11-06 The Samuel Roberts Noble Foundation, Inc. Production of proanthocyanidins to improve forage quality
CN101969959A (zh) * 2007-07-31 2011-02-09 利默里克生物制药公司 磷酸化吡喃酮类似物和方法
TWI324514B (en) 2008-02-26 2010-05-11 Univ Kaohsiung Medical Isoflavone derivatives and pharmaceutical compositions comprising the same
US20100009970A1 (en) 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
CN101301287A (zh) * 2008-06-12 2008-11-12 上海双科医药科技有限公司 射干异黄酮类化合物在制备抗肝炎药物中的应用
WO2010032248A2 (en) * 2008-09-17 2010-03-25 Yeda Research And Development Co. Ltd. Multifunctional albumin conjugates
WO2012003030A2 (en) 2010-04-23 2012-01-05 Kineta, Inc. Methods of identifying & using anti-viral compounds
WO2011133728A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
EP2918273B1 (en) 2011-02-25 2016-12-21 Kineta, Inc. Methods and cells for identifying rig-i pathway regulators

Also Published As

Publication number Publication date
CN102946881A (zh) 2013-02-27
US20110262482A1 (en) 2011-10-27
EP2560652A4 (en) 2013-08-14
EP2560652A2 (en) 2013-02-27
WO2011133728A3 (en) 2012-05-24
CA2798209A1 (en) 2011-10-27
IL222633A0 (en) 2012-12-31
KR20130055612A (ko) 2013-05-28
AU2011242689B2 (en) 2015-09-17
TW201139419A (en) 2011-11-16
US9408826B2 (en) 2016-08-09
AU2011242689A1 (en) 2012-12-13
MX2012012354A (es) 2013-03-07
JP2013527159A (ja) 2013-06-27
WO2011133728A2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
BR112012026644A2 (pt) compostos antivirais
BR112012026641A2 (pt) compostos antivirais
MX2014003889A (es) Compuestos antivirales.
ECSP17072474A (es) Métodos para tratar infecciones por el virus filoviridae
WO2011133729A3 (en) Anti-viral compounds
EA201101620A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
BR112013019643A2 (pt) inibidores de alk, uso e composição farmacêutica compreendendo os mesmos
EP2542545A4 (en) INHIBITORS OF HEPATITIS C-VIRUS NS5B POLYMERASE
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
BR112018006080A2 (pt) novos compostos bicíclicos como inibidores de dupla ação de atx/ca
EA201592075A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
MD4589C1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
EA201190224A1 (ru) Ингибиторы гепатита c, содержащие конденсированные кольца
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
PE20151433A1 (es) Nucleosidos sustituidos, nucleotidos y analogos de los mismos
WO2011133727A3 (en) Anti-viral compounds
BR112013002729A2 (pt) inibidores de vírus de hepatite c
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
BR112015011224A2 (pt) misturas de reação de pcr e métodos de usar as mesmas
EA201490643A1 (ru) Новые производные бетулиновой кислоты с противовирусной активностью
MX363270B (es) Composiciones y metodos para inhibir la polimerasa viral.
MX351818B (es) Compuestos antivirales.
BR112014008616A2 (pt) compostos antivirais

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE E US 61/327,579 DE 23/04/2010 REIVINDICADA NO PCT/US2011/033336 POR NAO CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI 2440 DE 10/10/2017 PARA APRESENTACAO DE DOCUMENTO DE CESSAO CORRETO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]